Breakpoint Therapeutics aims to progress the scientific development of initial-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company’s therapeutics target the DNA harm response in cancer cells with fix and replication pressure tolerance pathways, enabling the health care organisation and hospitals to produce medicine https://is.gd/VVmTMJ